2Janice EW, Mark M, Wayne DR, et al. Racial Disparities in CHDMortality from 1968 -1992 in the State Economic Areas Surrounding theARIC Study Communities [ J ]. Annals of Epidemiology, 1999,9(8): 472-480.
6Smith SC,Allen J,Blair SN,et al.AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease:2006 update endorsed by the National Heart,Lung,and Blood Institute.J Am Coll Cardiol,2006,47:2130-2139.
7Patrono C,Bachmann F,Baigent C et al.European Society of Cardiology.Expert consensus document on the use of antiplatelet agents.The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.Eur Heart J,2004,25:166-181.
8Grundy SM,Cleemam JI,Merz CN,et al.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines.J Am Coil Cardiol,2004,44:720-732.
9Snow V,Barry P,Fihn SD,et al.Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease:a clinical practice guideline from the American College of Physicians.Ann Intern Med,2004,141:562-567.
10Newby LK, La Pointe NM, Chen AY, et al. Long - term adherence to evidence - based secondary prevention therapies in coronary artery disease[J] . Circulation, 2006,113(2) :203.
